PT3619237T - Anticorpos contra antigénio carcinoembriónico para terapia e diagnóstico do cancro - Google Patents

Anticorpos contra antigénio carcinoembriónico para terapia e diagnóstico do cancro

Info

Publication number
PT3619237T
PT3619237T PT187224977T PT18722497T PT3619237T PT 3619237 T PT3619237 T PT 3619237T PT 187224977 T PT187224977 T PT 187224977T PT 18722497 T PT18722497 T PT 18722497T PT 3619237 T PT3619237 T PT 3619237T
Authority
PT
Portugal
Prior art keywords
diagnosis
antibodies against
cancer therapy
carcinoembryonic antigen
against carcinoembryonic
Prior art date
Application number
PT187224977T
Other languages
English (en)
Original Assignee
B Cell Design
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B Cell Design filed Critical B Cell Design
Publication of PT3619237T publication Critical patent/PT3619237T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT187224977T 2017-05-04 2018-05-03 Anticorpos contra antigénio carcinoembriónico para terapia e diagnóstico do cancro PT3619237T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305498.2A EP3398967A1 (en) 2017-05-04 2017-05-04 Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
PT3619237T true PT3619237T (pt) 2024-03-05

Family

ID=58707444

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187224977T PT3619237T (pt) 2017-05-04 2018-05-03 Anticorpos contra antigénio carcinoembriónico para terapia e diagnóstico do cancro

Country Status (10)

Country Link
US (1) US11427646B2 (pt)
EP (2) EP3398967A1 (pt)
AU (1) AU2018262648B2 (pt)
DK (1) DK3619237T5 (pt)
ES (1) ES2975798T3 (pt)
FI (1) FI3619237T3 (pt)
HU (1) HUE066183T2 (pt)
PL (1) PL3619237T3 (pt)
PT (1) PT3619237T (pt)
WO (1) WO2018202794A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025257185A1 (en) 2024-06-11 2025-12-18 Abcely Humanized anti-human-carcinoembryonic antigen antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers

Also Published As

Publication number Publication date
CA3062233A1 (en) 2018-11-08
AU2018262648B2 (en) 2024-08-08
US11427646B2 (en) 2022-08-30
HUE066183T2 (hu) 2024-07-28
DK3619237T5 (da) 2024-09-02
EP3619237B1 (en) 2024-01-17
FI3619237T3 (fi) 2024-04-19
WO2018202794A1 (en) 2018-11-08
EP3398967A1 (en) 2018-11-07
PL3619237T3 (pl) 2024-06-24
EP3619237A1 (en) 2020-03-11
US20200055952A1 (en) 2020-02-20
DK3619237T3 (da) 2024-04-08
ES2975798T3 (es) 2024-07-15
AU2018262648A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
IL274246A (en) Methods for diagnosing and treating cancer
ZA202002923B (en) Cd47 antibodies and uses thereof for treating cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL248511A0 (en) Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
IL265759A (en) Therapeutic and diagnostic methods for cancer
IL273071A (en) Treatment and diagnosis methods for cancer
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL260474B (en) Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment
HUE061874T2 (hu) Anti-PD-1 antitestek és besugárzás kombinált alkalmazása a rák kezelésére
IL260935A (en) Methods for treating hrg, her2-, er breast cancer using combined treatments that include an anti-erbb3 antibody
IL277861A (en) Antibodies specific to AXL for cancer treatment
SI3458102T1 (sl) Konjugati anti-cMet protitelo-zdravilo in postopki za njihovo uporabo
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
PT3512882T (pt) Anticorpos anti-c-met e conjugados anticorpo-fármaco dos mesmos para inibição tumoral eficaz
ZA202000851B (en) Antibodies useful in cancer diagnosis
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
IL281441A (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
ZA202005023B (en) L2a5 antibody or functional fragment thereof against tumour antigens
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
GB201613167D0 (en) Cancer and b-cell related disease therapy
IL255273A0 (en) igf-1r antibody and its use for cancer diagnosis
PL3619237T3 (pl) Przeciwciała przeciwko antygenowi rakowo-płodowemu w terapii i diagnostyce nowotworów złośliwych
ZA201707247B (en) Igf-1r antibody and its use for the diagnosis of cancer
GB201813137D0 (en) Cancer treatment with an antibody
SG11202007750PA (en) Cancer antigen peptide